This biotech firm has room to run despite surging nearly 500% in past year, Morgan Stanley says

Morgan Stanley upgraded Arrowhead Pharmaceuticals to overweight from equal weight and raised its price target to $100 from $78, implying 44.4% upside. The bank expects positive phase 3 data for Plozasiran in severe hypertriglyceridemia in 3Q26 to unlock a multibillion-dollar opportunity and support further upside. Arrowhead shares have already surged more than 473% over the past year, and 10 of 13 analysts now rate the stock buy or strong buy.

Analysis

The market is starting to re-rate ARWR less as a single-asset biotech and more as a platform with near-dated de-risking events. That matters because the stock has already moved far enough that incremental upside now depends on whether plozasiran can convert into a credible commercial franchise, not just on “good data.” In that setup, positive phase 3 results can drive a second leg higher if they expand addressable duration and reimbursement confidence, while any narrowing of the efficacy/safety margin would likely trigger a sharp multiple reset given how much optimism is already embedded.

The most interesting second-order effect is competitive positioning within the cardiometabolic obesity-adjacent universe. A clean readout would force investors to revisit the size of the triglyceride-lowering market, but more importantly it would validate RNAi as a modality in chronic primary-care-like markets where commercial scale, not just scientific novelty, drives valuation. That puts pressure on adjacent developers pursuing lipid and metabolic indications: capital can rotate away from earlier-stage stories and toward names with nearer monetization, especially if Arrowhead establishes a cleaner path to broad payer adoption than peptide or small-molecule alternatives.

The setup is still binary over the next 3-15 months. Near term, momentum can continue on anticipation alone, but the trade becomes vulnerable if the market starts to question how much of the opportunity is already capitalized after a 4-5x run. The main tail risk is not simply trial disappointment; it is a result that is technically positive yet commercially insufficient, which often hurts more because it strips away the “huge unmet market” narrative without providing an alternative catalyst.

Key Decisions for Investors

• Stay long ARWR into the 3Q26 catalyst, but size it as a catalyst trade rather than a core biotech holding; use staged adds on post-consolidation weakness with a 6-12 month horizon and a target for continued multiple expansion if phase 3 reads clean.
• Buy ARWR call spreads 3-6 months ahead of the expected data window to express upside while capping premium at risk; preferred structure is an out-of-the-money bull call spread to avoid paying full implied vol into the event.
• If already long, hedge with short-dated puts or a collar into the readout; the stock can fall sharply on “good but not great” data because expectations are elevated after the run.
• Relative-value long ARWR / short a basket of earlier-stage cardiometabolic or RNAi peers over the next 6-9 months; the trade should benefit if capital rotates toward de-risked assets with nearer commercialization.
• Trim into strength if ARWR trades ahead of the consensus view of fair value before data; the risk/reward worsens materially once the market fully prices in a best-case phase 3 outcome.